Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Nov 19

PMID 31737573

Citations 10

Authors

Lin Zhao

Jiarui Li

Chunmei Bai

Yongdu Nie

Guole Lin

Affiliations

Soon will be listed here.

Abstract

People with metastatic gastric cancer (GC) have a poor prognosis. The study aims to investigate the efficacy of multi-modality treatment for patients with metastatic GC. We retrospectively identified 267 patients with stage IV gastric cancer who were treated with systemic chemotherapy: 114 received multi-modality treatments, 153 received systematic chemotherapy alone. The survival of these two groups was compared by log rank test, the independent prognostic factors were investigated using univariate and multivariate analyses. The median survival of metastatic GC patients who received multi-modality treatment was significantly longer than those who received systematic chemotherapy alone (18.4 vs. 11.4 months, < 0.001). Multivariate analysis identified tumor histologic differentiation, CA19-9 level, previous curative resection, palliative gastrectomy, and metastasectomy as independent prognostic factors for overall survival. In the multimodality treatment group, patients who received palliative gastrectomy or metastasectomy had a longer survival than those who only received intraperitoneal chemotherapy or radiotherapy (21.6 vs. 15.2 months, = 0.014). Multi-modality treatments offer a survival benefit for patients with metastatic GC. Future prospective studies are needed to confirm the result.

Citing Articles

A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort.

Zhao Z, Dai E, Jin B, Deng P, Salehebieke Z, Han B Clin Transl Oncol. 2024; 27(1):135-150.

PMID: 38918302 PMC: 11735592. DOI: 10.1007/s12094-024-03576-4.

Zinc Finger Proteins in the War on Gastric Cancer: Molecular Mechanism and Clinical Potential.

Liu S, Liu X, Lin X, Chen H Cells. 2023; 12(9).

PMID: 37174714 PMC: 10177130. DOI: 10.3390/cells12091314.

Effect of multimodal chemotherapy on survival of gastric cancer with liver metastasis - a population based analysis.

Li X, Chen Z, Zhang Y, Zhang H, Niu H, Zheng C Front Oncol. 2023; 13:1064790.

PMID: 37007120 PMC: 10061116. DOI: 10.3389/fonc.2023.1064790.

Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery.

Zhang L, Li H, Wang T, Wang R, Cheng L, Wang G Cancers (Basel). 2022; 14(21).

PMID: 36358825 PMC: 9656785. DOI: 10.3390/cancers14215408.

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review.

Wang X, Zeng Y, Zhang J, Huang M, Yin B Front Oncol. 2022; 12:940263.

PMID: 35875121 PMC: 9304692. DOI: 10.3389/fonc.2022.940263.

References

Cho J, Lim J, Choi A, Choi S, Kim J, Choi S . Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Res Treat. 2015; 47(4):697-705. PMC: 4614195. DOI: 10.4143/crt.2013.175. View

Thomassen I, van Gestel Y, van Ramshorst B, Luyer M, Bosscha K, Nienhuijs S . Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2013; 134(3):622-8. DOI: 10.1002/ijc.28373. View

Ebinger S, Warschkow R, Tarantino I, Schmied B, Guller U, Schiesser M . Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer. 2015; 19(3):723-34. DOI: 10.1007/s10120-015-0541-9. View

Ye S, Wang L, Zuo Z, Bei Y, Liu K . The role of surgery and radiation in advanced gastric cancer: A population-based study of Surveillance, Epidemiology, and End Results database. PLoS One. 2019; 14(3):e0213596. PMC: 6413929. DOI: 10.1371/journal.pone.0213596. View

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

Fujitani K, Yang H, Mizusawa J, Kim Y, Terashima M, Han S . Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17(3):309-318. DOI: 10.1016/S1470-2045(15)00553-7. View

Sun W, Yan L . Gastric cancer: current and evolving treatment landscape. Chin J Cancer. 2016; 35(1):83. PMC: 5006607. DOI: 10.1186/s40880-016-0147-6. View

Thuss-Patience P, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K . Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011; 47(15):2306-14. DOI: 10.1016/j.ejca.2011.06.002. View

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

10.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

11.

Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker P, Piso P . Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis. Eur J Surg Oncol. 2016; 42(9):1261-7. DOI: 10.1016/j.ejso.2016.03.035. View

12.

Songun I, Putter H, Meershoek-Klein Kranenbarg E, Sasako M, van de Velde C . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11(5):439-49. DOI: 10.1016/S1470-2045(10)70070-X. View

13.

Misleh J, Santoro P, Strasser J, Bennett J . Multidisciplinary management of gastric cancer. Surg Oncol Clin N Am. 2013; 22(2):247-64. DOI: 10.1016/j.soc.2012.12.013. View

14.

Ajani J, DAmico T, Almhanna K, Bentrem D, Chao J, Das P . Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(10):1286-1312. DOI: 10.6004/jnccn.2016.0137. View

15.

Wang Y, Yu Y, Li W, Feng Y, Hou J, Ji Y . A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol. 2014; 73(6):1155-61. PMC: 4032640. DOI: 10.1007/s00280-014-2449-1. View

16.

Markar S, Mikhail S, Malietzis G, Athanasiou T, Mariette C, Sasako M . Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis. Ann Surg. 2016; 263(6):1092-101. DOI: 10.1097/SLA.0000000000001542. View

17.

Dugo D, Cananzi F, Persiani R, Agnes A, Biondi A . REGATTA trial: a call for the USA and Europe. Lancet Oncol. 2016; 17(3):261-262. DOI: 10.1016/S1470-2045(15)00619-1. View

18.

Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M . Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018; 36(19):1922-1929. DOI: 10.1200/JCO.2018.77.8613. View

19.

Wesolowski R, Lee C, Kim R . Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009; 10(9):903-12. DOI: 10.1016/S1470-2045(09)70136-6. View

20.

Hazard L, OConnor J, Scaife C . Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol. 2006; 12(10):1511-20. PMC: 4124282. DOI: 10.3748/wjg.v12.i10.1511. View